Vice President, Chemistry, Manufacturing, and Controls; CMC

Vice President, Chemistry, Manufacturing, and Controls (CMC)

Position Description

Juvena Therapeutics is seeking a seasoned and strategic leader to join our executive team as the Vice President of Chemistry, Manufacturing, and Controls (CMC). Reporting directly to the SVP of Drug Development, this pivotal role will be responsible for defining and executing the comprehensive CMC strategy for our portfolio from discovery through to clinical-stage development. The successful candidate will lead all aspects of process development, analytical development, and manufacturing, guiding our novel candidates from pre-clinical development and lead optimization through regulatory filings, formulation optimization, scaling, clinical trials and commercialization.

The VP of CMC will have expertise in biologics manufacturing and delivery, fusion proteins, and mammalian cell line-based protein synthesis. He/she will have experience and a strong understanding of the requirements for pre-filled syringes as well as drug-device combination development.

This is a critical leadership position requiring a blend of deep technical expertise, strategic vision, and operational excellence. The VP of CMC will oversee a primarily outsourced manufacturing model, building and managing strong relationships with a network of Contract Development and Manufacturing Organizations (CDMOs). The successful candidate will also oversee internal small scale production, protein engineering and lead optimization activities for assets in discovery and preclinical development.

As a key member of the leadership team, you will collaborate across functions to ensure that our CMC activities are fully aligned with our clinical, regulatory, and corporate goals.

Company Summary

Juvena Therapeutics is a clinical stage, venture-backed biotech company leveraging its AI-enabled platform to discover and advance tissue restorative biologics to tackle chronic muscle and metabolic diseases. The company’s approach stems from mapping the therapeutic potential of stem-cell secreted proteins and translating them into a growing pipeline of engineered biologics. Juvena is achieving this through a fully integrated, end-to-end platform, JuvNET, that combines a compounding database leveraging quantitative proteomics, multi-omics, and high content imaging to map secreted proteins to specific disease phenotypes, utilizing in silico and in vitro human cell screening, pharmacology, and protein engineering capabilities.

Juvena is progressing multiple clinical and preclinical programs, including a clinical stage, muscle regenerative biologic and a novel preclinical lipolysis inducing obesity asset with a unique mechanism.

Juvena’s lead asset, JUV-161, is a muscle regenerating fusion protein with broad indication potential, currently in Phase 1 studies in healthy volunteers, with the aim of developing the drug candidate for Myotonic Dystrophy Type 1 (DM1). Juvena’s obesity candidate, JUV-112, is based on a novel secreted protein with an orthogonal, non-appetite suppressing, energy expenditure based MOA (non-GLP-1/GIP mediated) for improved fat metabolism, including improved insulin sensitivity and adipose regulation.

JUV-112 is currently in lead optimization. Juvena is also identifying muscle targeting pro-metabolic and hypertrophic secreted proteins for Sarcopenic Obesity, with an active discovery collaboration with Eli Lilly. Additionally, Juvena has discovered and validated 55+ hits across 6 therapeutic areas including fibrotic, hepatic, pulmonary, metabolic, osteopathies and inflammatory diseases.

Juvena’s venture-backed preclinical programs were also supported by funding from the National Institute of Health (NIH) and the California Institute of Regenerative Medicine (CIRM). At Juvena we embrace a diversity of backgrounds, experience and approaches that all combine to lead us to world-class scientific results in an inclusive environment. To learn more about Juvena Therapeutics, visit  or follow the company on Linked In @Juvena-Therapeutics .

Position Location and work permit requirement

640 Galveston Dr. Redwood City, 94063

Strong preference for onsite work at our office,…